A Peek Into The Market Before The Trading Starts

Loading...
Loading...
Pre-open movers
US stock futures are lower this morning, as investors are awaiting new-home sales data. Futures for the Dow Jones Industrial Average dropped 19 points to 12,843.00 and S&P 500 index futures fell 3.30 points to 1,394.10. Nasdaq 100 futures declined 6.25 points to 2,635.00.
A Peek Into Global Markets
European markets were lower today. The STOXX Europe 600 Index fell 0.21%, London's FTSE 100 Index dropped 0.25%, French CAC 40 Index declined 0.40% and German DAX 30 index fell 0.15%. Asian markets ended lower, with Japan's Nikkei Stock Average dropping 1.22%, China's Shanghai Composite dropping 0.89% and Australia's S&P/ASX 200 falling 0.24%. Hong Kong's Hang Seng Index declined 0.62%.
Broker Recommendation
Analysts at Piper Jaffray downgraded Windstream
WIN
from “neutral” to “underweight.” The target price for Windstream has been lowered from $8 to $6.50. Windstream shares gained 0.72% to $8.37 in after-hours trading.
Breaking news
  • Toll Brothers TOL recently purchased 692 acres in Montgomery County, the largest land contract for the national home builder since entering the Houston market in 2009. To read the full news, click here.
  • AVEO Oncology AVEO and Astellas Pharma today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma (RCC). To read the full news, click here.
  • Curis CRIS today announced that it has licensed from Genentech, a member of the Roche Group, RHHBY, exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins. To read the full news, click here.
  • Forest Laboratories, FRX and Gedeon Richter Plc. Announced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors. To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsFuturesGlobalPre-Market OutlookMarketsPiper JaffrayUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...